Genzyme Tissue Repair (GZTR) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genzyme Tissue Repair (GZTR)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Knighty Tin who wrote (2520)	3/6/2000 11:44:00 AM
From: satish kamat	Read Replies (1) of 2553

<<I know I should sell>> why would you want to sell and leave money on the table? Based on $37 a share for the merged company, this share is valued at least $12.4. But the merged company has market cap of $1.24B and will have the revenue of $250MM. That is a puny P/S of 5. Assuming a second tier biotech with a strong portfolio and pipeline, P/S should be more like 7.5-9. Am I missing something here? anyway more complete story is here: biz.yahoo.com satish kamat

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next